- July 3, 2018
- Posted by: PharmaScroll
- Category:
As per a recent Appraisal consultation document issued by NICE, Ocrelizumab is not recommended, within its marketing authorisation, for treating early primary progressive multiple sclerosis with imaging features characteristic of inflammatory activity in adults. NICE further stated that this recommendation is not intended to affect treatment with ocrelizumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.
NICE acknowledged that there are currently no disease-modifying treatments approved for primary progressive multiple sclerosis. Clinical trial results show that ocrelizumab can slow the worsening of disability in people with the condition, including loss of upper limb function. However, NICE added that the most plausible cost-effectiveness estimates for ocrelizumab compared with best supportive care alone are much higher than those NICE normally considers an acceptable use of NHS resources in all scenarios presented by the company. Therefore, ocrelizumab cannot be recommended for treating early primary progressive multiple sclerosis in adults.
About Pharmascroll:
Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.
To read more news about Multiple Sclerosis, visit https://pharmascroll.com/news-category/multiple-sclerosis/
News Source: https://www.nice.org.uk/guidance/GID-TA10153/documents/appraisal-consultation-document